Akari Therapeutics Plc (AKTX)
8.72
-0.12
(-1.36%)
USD |
NASDAQ |
Oct 02, 16:00
8.65
-0.07
(-0.80%)
After-Hours: 20:00
Akari Therapeutics Net Income (Quarterly) : -4.816M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.816M |
| March 31, 2026 | -14.43M |
| December 31, 2025 | -5.290M |
| September 30, 2025 | -6.36M |
| June 30, 2025 | -1.918M |
| March 31, 2025 | -3.705M |
| December 31, 2024 | -3.737M |
| September 30, 2024 | -2.895M |
| June 30, 2024 | -7.558M |
| March 31, 2024 | -5.566M |
| March 31, 2023 | 1.001M |
| June 30, 2022 | -5.68M |
| March 31, 2022 | -5.176M |
| December 31, 2021 | -5.788M |
| September 30, 2021 | -1.451M |
| June 30, 2021 | -4.346M |
| March 31, 2021 | -5.838M |
| December 31, 2020 | -6.822M |
| September 30, 2020 | 0.9135M |
| June 30, 2020 | -7.440M |
| March 31, 2020 | -3.745M |
| December 31, 2019 | -7.878M |
| Date | Value |
|---|---|
| September 30, 2019 | -2.565M |
| June 30, 2019 | -4.117M |
| March 31, 2019 | -2.545M |
| December 31, 2018 | -3.513M |
| September 30, 2018 | -3.593M |
| June 30, 2018 | -8.022M |
| March 31, 2018 | -1.339M |
| December 31, 2017 | -9.293M |
| September 30, 2017 | -10.38M |
| June 30, 2017 | -0.32M |
| March 31, 2017 | -12.58M |
| December 31, 2016 | -7.589M |
| September 30, 2016 | -0.4181M |
| June 30, 2016 | -6.451M |
| March 31, 2016 | -2.833M |
| December 31, 2015 | 6.423M |
| September 30, 2015 | -48.84M |
| June 30, 2015 | -1.624M |
| March 31, 2015 | -2.174M |
| December 31, 2013 | -1.385M |
| September 30, 2013 | 0.4159M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| DBV Technologies SA | -- |
| Cellectis SA | -21.79M |
| Bicycle Therapeutics Plc | -50.42M |
| Autolus Therapeutics Plc | -39.18M |
| Evaxion AS | -3.724M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 4.816M |
| EPS Diluted (Quarterly) | -2.404 |
| Enterprise Value | 8.202M |
| Earnings Yield | -226.8% |